Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study

Matsuhiko Hayashi, Shunya Uchida, Tetsuya Kawamura, Michio Kuwahara, Masaomi Nangaku, Yasuhiko Iino

研究成果: Article

5 引用 (Scopus)

抄録

Background: We conducted a randomized, open-label trial to determine which of the antihypertensive drugs was most beneficial for CKD patients with hypertension in spite of treatment with an angiotensin receptor blocker (ARB). Methods: Patients 20–75 years of age who had CKD according to the definition in the K/DOQI Guidelines and hypertension (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg) with the usual dose of an ARB were randomly assigned to receive losartan 50 mg plus 5 mg of the calcium channel blocker amlodipine (CCB group, n = 37), 5 mg of the angiotensin-converting enzyme inhibitor enalapril (ACEI group, n = 36), or 12.5 mg of the thiazide diuretic hydrochlorothiazide (HCTZ group, n = 36). The primary endpoints were changes in blood pressure (BP), ratio of urinary excretion of protein to creatinine (UPCR), tolerability, and eGFR during the 12-month treatment period compared with control period. Results: There were no significant differences in BP and tolerability between the three groups. The percentage changes in UPCR at 12 months after start of the combination therapy were significantly different in the HCTZ group (−26.3 ± 11.1 %, mean ± SE) and CCB group (+46.7 ± 33.6 %, p 

元の言語English
ページ(範囲)925-932
ページ数8
ジャーナルClinical and Experimental Nephrology
19
発行部数5
DOI
出版物ステータスPublished - 2015 10 1

Fingerprint

Chronic Renal Insufficiency
Prospective Studies
Blood Pressure
Hydrochlorothiazide
Angiotensin Receptor Antagonists
Therapeutics
Hypertension
Sodium Chloride Symporter Inhibitors
Amlodipine
Enalapril
Losartan
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Creatinine
Guidelines
Proteins

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

これを引用

Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease : results of the PROTECT-CKD study. / Hayashi, Matsuhiko; Uchida, Shunya; Kawamura, Tetsuya; Kuwahara, Michio; Nangaku, Masaomi; Iino, Yasuhiko.

:: Clinical and Experimental Nephrology, 巻 19, 番号 5, 01.10.2015, p. 925-932.

研究成果: Article

Hayashi, Matsuhiko ; Uchida, Shunya ; Kawamura, Tetsuya ; Kuwahara, Michio ; Nangaku, Masaomi ; Iino, Yasuhiko. / Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease : results of the PROTECT-CKD study. :: Clinical and Experimental Nephrology. 2015 ; 巻 19, 番号 5. pp. 925-932.
@article{4ed56c31521a432fb590d70d38f3a278,
title = "Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study",
abstract = "Background: We conducted a randomized, open-label trial to determine which of the antihypertensive drugs was most beneficial for CKD patients with hypertension in spite of treatment with an angiotensin receptor blocker (ARB). Methods: Patients 20–75 years of age who had CKD according to the definition in the K/DOQI Guidelines and hypertension (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg) with the usual dose of an ARB were randomly assigned to receive losartan 50 mg plus 5 mg of the calcium channel blocker amlodipine (CCB group, n = 37), 5 mg of the angiotensin-converting enzyme inhibitor enalapril (ACEI group, n = 36), or 12.5 mg of the thiazide diuretic hydrochlorothiazide (HCTZ group, n = 36). The primary endpoints were changes in blood pressure (BP), ratio of urinary excretion of protein to creatinine (UPCR), tolerability, and eGFR during the 12-month treatment period compared with control period. Results: There were no significant differences in BP and tolerability between the three groups. The percentage changes in UPCR at 12 months after start of the combination therapy were significantly different in the HCTZ group (−26.3 ± 11.1 {\%}, mean ± SE) and CCB group (+46.7 ± 33.6 {\%}, p ",
keywords = "Angiotensin receptor blocker, Angiotensin-converting enzyme inhibitor, Calcium channel blocker, Chronic kidney disease, Diuretics",
author = "Matsuhiko Hayashi and Shunya Uchida and Tetsuya Kawamura and Michio Kuwahara and Masaomi Nangaku and Yasuhiko Iino",
year = "2015",
month = "10",
day = "1",
doi = "10.1007/s10157-015-1091-5",
language = "English",
volume = "19",
pages = "925--932",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease

T2 - results of the PROTECT-CKD study

AU - Hayashi, Matsuhiko

AU - Uchida, Shunya

AU - Kawamura, Tetsuya

AU - Kuwahara, Michio

AU - Nangaku, Masaomi

AU - Iino, Yasuhiko

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: We conducted a randomized, open-label trial to determine which of the antihypertensive drugs was most beneficial for CKD patients with hypertension in spite of treatment with an angiotensin receptor blocker (ARB). Methods: Patients 20–75 years of age who had CKD according to the definition in the K/DOQI Guidelines and hypertension (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg) with the usual dose of an ARB were randomly assigned to receive losartan 50 mg plus 5 mg of the calcium channel blocker amlodipine (CCB group, n = 37), 5 mg of the angiotensin-converting enzyme inhibitor enalapril (ACEI group, n = 36), or 12.5 mg of the thiazide diuretic hydrochlorothiazide (HCTZ group, n = 36). The primary endpoints were changes in blood pressure (BP), ratio of urinary excretion of protein to creatinine (UPCR), tolerability, and eGFR during the 12-month treatment period compared with control period. Results: There were no significant differences in BP and tolerability between the three groups. The percentage changes in UPCR at 12 months after start of the combination therapy were significantly different in the HCTZ group (−26.3 ± 11.1 %, mean ± SE) and CCB group (+46.7 ± 33.6 %, p 

AB - Background: We conducted a randomized, open-label trial to determine which of the antihypertensive drugs was most beneficial for CKD patients with hypertension in spite of treatment with an angiotensin receptor blocker (ARB). Methods: Patients 20–75 years of age who had CKD according to the definition in the K/DOQI Guidelines and hypertension (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg) with the usual dose of an ARB were randomly assigned to receive losartan 50 mg plus 5 mg of the calcium channel blocker amlodipine (CCB group, n = 37), 5 mg of the angiotensin-converting enzyme inhibitor enalapril (ACEI group, n = 36), or 12.5 mg of the thiazide diuretic hydrochlorothiazide (HCTZ group, n = 36). The primary endpoints were changes in blood pressure (BP), ratio of urinary excretion of protein to creatinine (UPCR), tolerability, and eGFR during the 12-month treatment period compared with control period. Results: There were no significant differences in BP and tolerability between the three groups. The percentage changes in UPCR at 12 months after start of the combination therapy were significantly different in the HCTZ group (−26.3 ± 11.1 %, mean ± SE) and CCB group (+46.7 ± 33.6 %, p 

KW - Angiotensin receptor blocker

KW - Angiotensin-converting enzyme inhibitor

KW - Calcium channel blocker

KW - Chronic kidney disease

KW - Diuretics

UR - http://www.scopus.com/inward/record.url?scp=84944070415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944070415&partnerID=8YFLogxK

U2 - 10.1007/s10157-015-1091-5

DO - 10.1007/s10157-015-1091-5

M3 - Article

C2 - 25680887

AN - SCOPUS:84944070415

VL - 19

SP - 925

EP - 932

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 5

ER -